Streetbeat News

Regulatory

IINN

IINNW

Inspira Technologies (IINN, IINNW) has signed a non-binding LOI with Shamir Medical Center in Israel for the clinical evaluation of its INSPIRA ART100 device, aimed at improving life-support care. This collaboration, pending AMAR approval, will assess the device's integration, efficiency, and impact on healthcare delivery. The evaluation will be led by Dr. Eduard Ilgiyaev, with the hospital procuring necessary disposables. Inspira anticipates FDA approval and sees this as a step towards global market adoption.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:08 pm

SSNC

SS&C Technologies has formed a strategic partnership with Regnology to deliver a fully integrated risk and regulatory reporting solution. This collaboration aims to streamline compliance processes and provide analytical insights, helping institutions quickly adapt to regulatory changes.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:04 pm

NVVE

Nuvve Holding Corp. (NVVE), a green energy technology company specializing in vehicle-to-grid (V2G) technology, announced it has regained compliance with the Nasdaq minimum bid price rule. The company's stock had a closing bid price of $1.00 or greater for 10 consecutive business days, from January 22, 2023, to February 2, 2024, meeting the Nasdaq Listing Rule 5550(a)(2) requirements.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:04 pm

SNES

SenesTech, Inc. (NASDAQ:SNES) has entered into an exclusive distribution agreement with Evicom to distribute its Evolve Soft Bait fertility control product in Australia and New Zealand. This partnership aims to address the demand for environmentally sustainable pest control solutions, particularly in response to Australia's rat plagues and New Zealand's efforts to eradicate invasive Norway rats by 2050. The agreement includes annual minimums and mandates Evicom to lead regulatory approvals in the target markets.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 2:03 pm

ATGE

BHC

Fahmi Quadir, known as 'The Assassin' for her successful short-selling strategies, targets Adtalem Global Education Inc. (NYSE:ATGE) in a new report, causing its shares to drop by as much as 23%. Quadir criticizes Adtalem for its reliance on federal tax dollars, calling it 'uninvestable.' Adtalem, previously known as DeVry University, has faced controversy before, including a significant student debt waiver for its graduates by the Biden administration. Adtalem's management refutes Quadir's claims, emphasizing their positive student outcomes and relationships with creditors and regulators.

Portfolio Pulse from Caleb Naysmith

February 08, 2024 | 1:59 pm

SBET

SharpLink Gaming has regained compliance with Nasdaq's listing requirements, ensuring its continued listing on the exchange. This development is significant for the company and its investors, as it addresses previous concerns regarding its listing status.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:47 pm

MCHP

Microchip Technology (NASDAQ:MCHP) has achieved ISO/SAE 21434 certification for its corporate processes related to automotive cybersecurity, as audited by UL Solutions. This standard, developed by ISO and SAE International, sets rigorous requirements for cybersecurity risk management across the automotive product lifecycle. The certification confirms Microchip's commitment to high cybersecurity standards in automotive design, benefiting customers by easing the compliance burden for electronic control units incorporating Microchip's security products.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:22 pm

SRTS

Sensus Healthcare has been granted U.S. Patent No. 11,894,123 B2 for a 'Radiotherapy Mobile and Wireless Device Workflow Management System.' This patent represents a significant technological advancement in the management and delivery of radiotherapy, potentially enhancing the efficiency and effectiveness of treatments offered by Sensus Healthcare.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:20 pm

QNRX

Quoin Pharmaceuticals has filed for U.S. and international patent applications for a novel combination product aimed at treating Netherton Syndrome. This move could potentially strengthen Quoin's position in the dermatological treatment market and protect its innovative approach from competitors.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:18 pm

ABBV

AbbVie has launched VYALEV, a novel subcutaneous 24-hour infusion therapy for advanced Parkinson's disease (aPD) in Canada, marking the first new non-surgical treatment option in a decade. VYALEV, which is designed to control motor fluctuations in aPD patients not adequately managed by oral medications, has shown efficacy in clinical trials by reducing motor fluctuations and improving sleep quality and life quality. This launch underscores AbbVie's commitment to addressing neurological disorders and provides a significant new treatment option for the over 100,000 Canadians living with Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 1:16 pm